Mitochondrial Fatty Acid Oxidation Disorders: Laboratory Diagnosis, Pathogenesis, and the Complicated Route to Treatment

키워드

참고문헌 (71)

1. Longo N, "Carnitine transport and fatty acid oxidation", Biochim Biophys Acta Mol Cell Res, 1863, pp.2422~2435 (2016)
2. Houten SM, "A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation", J Inherit Metab Dis, 33, pp.469~477 (2010)
3. Wanders RJ, "Biochemistry of mammalian peroxisomes revisited", Annu Rev Biochem, 75, pp.295~332 (2006)
4. Van Veldhoven PP, "Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism", J Lipid Res, 51, pp.2863~2895 (2010)
5. Wanders RJ, "Metabolic interplay between peroxisomes and other subcellular organelles including mitochondria and the endoplasmic reticulum", Front Cell Dev Biol, 3, pp.83~ (2016)
6. Knottnerus SJ, "Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle", Rev Endocr Metab Disord, 19, pp.93~106 (2018)
7. Spiekerkoetter U, "Mitochondrial fatty acid oxidation disorders : clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening", J Inherit Metab Dis, 33, pp.527~532 (2010)
8. Bonnet D, "Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children", Circulation, 100, pp.2248~2253 (1999)
9. Baruteau J, "Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects : a French pediatric study from 187 patients. Complementary data", J Inherit Metab Dis, 37, pp.137~139 (2014)
10. Baruteau J, "Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects : a French pediatric study of 187 patients", J Inherit Metab Dis, 36, pp.795~803 (2013)
11. Kim TT, "The role of CD36 in the regulation of myocardial lipid metabolism", Biochim Biophys Acta, 1861, pp.1450~1460 (2016)
12. Glatz JF, "Dynamic role of the transmembrane glycoprotein CD36(SR-B2)in cellular fatty acid uptake and utilization", J Lipid Res, 59, pp.1084~1093 (2018)
13. Son NH, "Endothelial cell CD36 optimizes tissue fatty acid uptake", J Clin Invest, 128, pp.4329~4342 (2018)
14. Vaz FM, "Carnitine biosynthesis in mammals", Biochem J, 361, pp.417~429 (2002)
15. Longo N, "Disorders of carnitine transport and the carnitine cycle", Am J Med Genet C Semin Med Genet (2006)
16. McGarry JD, "Regulation of hepatic fatty acid oxidation and ketone body production", Annu Rev Biochem, 49, pp.395~420 (1980)
17. McGarry JD, "The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis", Eur J Biochem, 244, pp.1~14 (1997)
18. McGarry JD, "A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis", J Clin Invest, 60, pp.265~270 (1977)
19. Saudubray JM, "Recognition and management of fatty acid oxidation defects : a series of 107 patients", J Inherit Metab Dis, 22, pp.488~502 (1999)
20. Boese EA, "Characterization of chorioretinopathy associated with mitochondrial trifunctional protein disorders : long-term follow-up of 21 cases", Ophthalmology, 123, pp.2183~2195 (2016)
21. Przyrembel H, "Glutaric aciduria type II : report on a previously undescribed metabolic disorder", Clin Chim Acta, 66, pp.227~239 (1976)
22. Horvath R, "Update on clinical aspects and treatment of selected vitamin-responsive disorders II(riboflavin and CoQ 10)", J Inherit Metab Dis, 35, pp.679~687 (2012)
23. Grünert SC, "Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency", Orphanet J Rare Dis, 9, pp.117~ (2014)
24. Loehr JP, "Glutaric acidemia type II : heterogeneity of clinical and biochemical phenotypes", Pediatr Res, 27, pp.311~315 (1990)
25. van Rijt WJ, "Prediction of disease severity in multiple acyl-CoA dehydrogenase deficiency : a retrospective and laboratory cohort study", J Inherit Metab Dis, 42, pp.878~889 (2019)
26. Sathasivam S, "Brown-Vialetto-Van Laere syndrome", Orphanet J Rare Dis, 3, pp.9~ (2008)
27. Dipti S, "Brown-Vialetto-Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease", Brain Dev, 27, pp.443~446 (2005)
28. Green P, "Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54", Am J Hum Genet, 86, pp.485~489 (2010)
29. Haack TB, "Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndrome", J Inherit Metab Dis, 35, pp.943~948 (2012)
30. Johnson JO, "Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease", Brain, 135, pp.2875~2882 (2012)
31. Jaeger B, "Clinical presentation and outcome of riboflavin transporter deficiency : mini review after five years of experience", J Inherit Metab Dis, 39, pp.559~564 (2016)
32. O'Callaghan B, "An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency", J Inherit Metab Dis, 42, pp.598~607 (2019)
33. Olsen RK, "Riboflavin-responsive and-non-responsive mutations in FAD synthase cause multiple acyl-CoA dehydrogenase and combined respiratory-chain deficiency", Am J Hum Genet, 98, pp.1130~1145 (2016)
34. Ryder B, "A novel truncating FLAD1 variant, causing multiple acyl-CoA dehydrogenase deficiency(MADD)in an 8-year-old boy", JIMD Rep, 45, pp.37~44 (2019)
35. Mosegaard S, "Riboflavin deficiency—implications for general human health and inborn errors of metabolism", Int J Mol Sci, 21, pp.3847~ (2020)
36. Henriques BJ, "Emerging roles for riboflavin in functional rescue of mitochondrial β-oxidation flavoenzymes", Curr Med Chem, 17, pp.3842~3854 (2010)
37. Schiff M, "SLC25A32 mutations and riboflavin-responsive exercise intolerance", N Engl J Med, 374, pp.795~797 (2016)
38. Hellebrekers DM, "Novel SLC25A32 mutation in a patient with a severe neuromuscular phenotype", Eur J Hum Genet, 25, pp.886~888 (2017)
39. Wanders RJ, "The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results", J Inherit Metab Dis, 33, pp.479~494 (2010)
40. Diekman EF, "Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency", Genet Med, 17, pp.989~994 (2015)
41. Bleeker JC, "Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency", J Inherit Metab Dis, 42, pp.159~168 (2019)
42. palmitic acid : an improved tool for the diagnosis of fatty acid oxidation defects, "Clin Chim Acta", 1999, 1~17
43. Iafolla AK, "Medium-chain acyl-coenzyme A dehydrogenase deficiency : clinical course in 120 affected children", J Pediatr, 124, pp.409~415 (1994)
44. Pena LD, "Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database", Mol Genet Metab, 118, pp.272~281 (2016)
45. Palmieri F, "The mitochondrial transporter family SLC25 : identification, properties and physiopathology", Mol Aspects Med, 34, pp.465~484 (2013)
46. Chua BH, "Reversible inhibition of adenine nucleotide translocation by long chain acyl-CoA esters in bovine heart mitochondria and inverted submitochondrial particles. Comparison with atractylate and bongkrekic acid", J Biol Chem, 252, pp.6711~6714 (1977)
47. Neess D, "Long-chain acyl-CoA esters in metabolism and signaling : role of acyl-CoA binding proteins", Prog Lipid Res, 59, pp.1~25 (2015)
48. Spiekerkoetter U, "Treatment recommendations in long-chain fatty acid oxidation defects : consensus from a workshop", J Inherit Metab Dis, 32, pp.498~505 (2009)
49. Spiekerkoetter U, "Update on mitochondrial fatty acid oxidation disorders", J Inherit Metab Dis, 33, pp.467~468 (2010)
50. Arnold GL, "A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency", Mol Genet Metab, 96, pp.85~90 (2009)
51. Roe CR, "Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride", J Clin Invest, 110, pp.259~269 (2002)
52. Roe CR, "Carnitine palmitoyltransferase II deficiency : successful anaplerotic diet therapy", Neurology, 71, pp.260~264 (2008)
53. Roe CR, "Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin : review of 15 years experience", Mol Genet Metab, 116, pp.260~268 (2015)
54. Vockley J, "Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders(LC-FAOD)", J Inherit Metab Dis, 42, pp.169~177 (2019)
55. Vockley J, "Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders", Mol Genet Metab, 119, pp.223~231 (2016)
56. Gillingham MB, "Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders : a double blinded, randomized controlled trial", J Inherit Metab Dis, 40, pp.831~843 (2017)
57. Vockley J, "Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: results from an open-label, long-term extension study", J Inherit Metab Dis. (2020)
58. Djouadi F, "Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders", Hum Mol Genet, 14, pp.2695~2703 (2005)
59. Gobin-Limballe S, "Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts : toward a genotype-based therapy", Am J Hum Genet, 81, pp.1133~1143 (2007)
60. Djouadi F, "Mitochondrial trifunctional protein deficiency in human cultured fibroblasts : effects of bezafibrate", J Inherit Metab Dis, 39, pp.47~58 (2016)
61. Bonnefont JP, "Bezafibrate for an inborn mitochondrial beta-oxidation defect", N Engl J Med, 360, pp.838~840 (2009)
62. Bonnefont JP, "Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency", Clin Pharmacol Ther, 88, pp.101~108 (2010)
63. Ørngreen MC, "Bezafibrate in skeletal muscle fatty acid oxidation disorders : a randomized clinical trial", Neurology, 82, pp.607~613 (2014)
64. Van Hove JL, "D, L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency(MADD)", Lancet, 361, pp.1433~1435 (2003)
65. Clarke K, "Kinetics, safety and tolerability of(R)-3-hydroxybutyl(R)-3-hydroxybutyrate in healthy adult subjects", Regul Toxicol Pharmacol, 63, pp.401~408 (2012)
66. Cox PJ, "Nutritional ketosis alters fuel preference and thereby endurance performance in athletes", Cell Metab, 24, pp.256~268 (2016)
67. Bleeker JC, "Nutritional ketosis improves exercise metabolism in patients with very long-chain acyl-CoA dehydrogenase deficiency", J Inherit Metab Dis, 43, pp.787~799 (2020)
68. Knottnerus SJ, "Electrophysiological abnormalities in VLCAD deficient hiPSC-cardiomyocytes can be improved by lowering accumulation of fatty acid oxidation intermediates", Int J Mol Sci, 21, pp.2589~ (2020)
69. Wu J, "Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes", Am J Physiol, 266, pp.H1034~H1046 (1994)
70. Wu J, "Influence of long-chain acylcarnitines on voltage-dependent calcium current in adult ventricular myocytes", Am J Physiol, 263, pp.H410~H417 (1992)
71. Mészàros J, "Electrophysiological effects of L-palmitoylcarnitine in single ventricular myocytes", Am J Physiol, 258, pp.H931~H938 (1990)

관련 논문AI추천